Compare · CI vs VRDN
CI vs VRDN
Side-by-side comparison of The Cigna Group (CI) and Viridian Therapeutics Inc. (VRDN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and VRDN operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $75.14B, about 42.9x VRDN ($1.75B).
- CI has been more active in the news (18 items in the past 4 weeks vs 15 for VRDN).
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Viridian Therapeutics Inc.
- Price
- $286.00+0.71%
- $16.59-2.38%
- Market cap
- $75.14B
- $1.75B
- 1M return
- -
- +7.90%
- 1Y return
- -
- +29.95%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 18
- 15
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Viridian Therapeutics Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Latest CI
- SEC Form 10-Q filed by The Cigna Group
- The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Cigna Group Reports Strong First Quarter 2026 Results, Raises 2026 Outlook
- The Cigna Group filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Foss Eric J was granted 782 shares, increasing direct ownership by 2% to 36,696 units (SEC Form 4)
- Director Mcclellan Mark B. was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Zarcone Donna F was granted 782 shares, increasing direct ownership by 3% to 27,517 units (SEC Form 4)
- Director Hathi Neesha was granted 782 shares, increasing direct ownership by 23% to 4,151 units (SEC Form 4)
- Director Mazzarella Kathleen M was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Kurian George was granted 782 shares, increasing direct ownership by 21% to 4,560 units (SEC Form 4)
Latest VRDN
- SEC Form FWP filed by Viridian Therapeutics Inc.
- SEC Form FWP filed by Viridian Therapeutics Inc.
- SEC Form 305B2 filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
- SEC Form 424B5 filed by Viridian Therapeutics Inc.
- SEC Form 424B5 filed by Viridian Therapeutics Inc.
- SEC Form FWP filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
- Viridian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form 10-Q filed by Viridian Therapeutics Inc.